搜尋結果
2024年4月27日 · Mr Teo Ser Luck has been re-elected as President of ISCA for a second term. Mr Teo is joined by newly elected office bearers: Vice President: Mr Choo Eng Beng. Vice President: Ms Judy Ng. Treasurer: Ms Jocelyn Goh Chern Ni. Secretary: Mr Lee Boon Teck. The newly-elected and re-elected Council Members will serve as ISCA Council Members until ...
2024年4月25日 · 港聞. 衞生署邀請就「護齒同行」提交計劃書. 04月25日 15:30 香港政府新聞公報. 衞生署今日（四月二十五日）邀請有興趣的機構，就「護齒同行」提交服務計劃書。 「護齒同行」旨在： 為合資格的服務使用者，透過行為管理、意識鎮靜、深層監測麻醉或全身麻醉，免費提供牙科護理服務；及. 向合資格服務使用者、其父母、家人、合法監護人及護理人員提供口腔護理教育以促進口腔健康。 「護齒同行」今個服務年度於二 二四年七月十五日完結。 有興趣的機構可就新服務年期，即由二 二四年七月十六日至二 二七年三月三十一日止，提交服務建議書。 由新服務年度起，「護齒同行」將擴展至涵蓋自閉症譜系障礙患者，申請者必須符合以下所有要求： 根據《稅務條例》（第112章）第88條獲豁免繳稅的非牟利機構；
2024年4月30日 · Shiv Shivaraman, Partner & Managing Director and Asia Region Leader at AlixPartners, said, “Lisa’s hands-on operations expertise and extensive experience across Greater China and Southeast Asia further strengthens our consumer and retail capabilities. Her ...
2024年4月17日 · SINGAPORE – Media OutReach Newswire – 17 April 2024 – Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind. The Aptegra ™ CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients ...
2024年5月22日 · Assess and manage risks; Log and record their AI use; Report to internal board, governance and audit committees; Satisfy external compliance and regulatory requirements and. Have an audit trail of reviews and updates. The Kim Application is divided into two sections.
2024年5月15日 · Emphasising the Importance of Maintaining Good Oral Hygiene Habits Neglecting oral hygiene can cause a range of dental issues such as cavities, gum disease, and bad breath. Over time, these untreated problems can escalate and progress to affect the surrounding teeth, soft tissue, and bone, potentially leading to severe systemic diseases.
2024年4月30日 · Organon, a global women’s healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene ®, an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream, 3.6 ...
